Shares of InMed Pharmaceuticals Inc. (INM) are up nearly 350% at $0.66 in premarket trading today after the company confirmed that its investigational drug INM-901 as an oral formulation will be utilized in its development programs for Alzheimer's disease.
INM-901, a proprietary small molecule drug candidate currently in preclinical testing, has shown in studies that it can be administered orally and achieve therapeutic brain levels similar to those attained via intraperitoneal (IP) injection. IP injection is a standard method used in preclinical research for neurodegenerative diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com